Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666

ACS Medicinal Chemistry Letters

Volumn 7, Issue 2, 2016, Pages 162-166

  Duncan, Kenneth W ^a   Rioux, Nathalie ^a,b   Boriack Sjodin, P Ann ^a   Munchhof, Michael J ^a   Reiter, Lawrence A ^a   Majer, Christina R ^a,c   Jin, Lei ^a,e   Johnston, L Danielle ^a   Chan Penebre, Elayne ^a   Kuplast, Kristy G ^a   Porter Scott, Margaret ^a,d   Pollock, Roy M ^a,c   Waters, Nigel J ^a   Smith, Jesse J ^a   Moyer, Mikel P ^a,f   Copeland, Robert A ^a   Chesworth, Richard ^a  

^a EPIZYME INC   (United States)

^b EISAI INC   (United States)

^c Warp Drive Bio ^*  (United States)

^d GENENTECH INC   (United States)

^e Agile Biostructure Solutions   (United States)

^f Raze Therapeutics   (United States)

Author keywords

Methyltransferase; PRMT5; property based optimization; structure guided design

Indexed keywords

ANTINEOPLASTIC AGENT; EPZ 015666; EPZ 015866; METHYLTRANSFERASE INHIBITOR; PROTEIN METHYLTRANSFERASE; PROTEIN METHYLTRANSFERASE 5; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHEMICAL ANALYSIS; CHEMICAL REACTION; CLINICAL PHARMACOLOGY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MEDICINAL CHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; STRUCTURE ANALYSIS;

EID: 84958977075     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/acsmedchemlett.5b00380     Document Type: Article

References (16)

1. Kaniskan, H. U.; Konze, K. D.; Jin, J. Selective inhibitors of protein methyltransferases J. Med. Chem. 2015, 58, 1596-629 10.1021/jm501234a
2. Cho, E. C.; Zheng, S.; Munro, S.; Liu, G.; Carr, S. M.; Moehlenbrink, J.; Lu, Y. C.; Stimson, L.; Khan, O.; Konietzny, R.; McGouran, J.; Coutts, A. S.; Kessler, B.; Kerr, D. J.; Thangue, N. B. Arginine methylation controls growth regulation by E2F-1 EMBO J. 2012, 31, 1785-97 10.1038/emboj.2012.17
3. Chung, J.; Karkhanis, V.; Tae, S.; Yan, F.; Smith, P.; Ayers, L. W.; Agostinelli, C.; Pileri, S.; Denis, G. V.; Baiocchi, R. A.; Sif, S. Protein arginine methyltransferase 5 (PRMT5) inhibition induces lymphoma cell death through reactivation of the retinoblastoma tumor suppressor pathway and polycomb repressor complex 2 (PRC2) silencing J. Biol. Chem. 2013, 288, 35534-47 10.1074/jbc.M113.510669
4. Pal, S.; Baiocchi, R. A.; Byrd, J. C.; Grever, M. R.; Jacob, S. T.; Sif, S. Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma EMBO J. 2007, 26, 3558-69 10.1038/sj.emboj.7601794
5. Pal, S.; Vishwanath, S. N.; Erdjument-Bromage, H.; Tempst, P.; Sif, S. Human SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes Mol. Cell. Biol. 2004, 24, 9630-45 10.1128/MCB.24.21.9630-9645.2004
6. Powers, M. A.; Fay, M. M.; Factor, R. E.; Welm, A. L.; Ullman, K. S. Protein arginine methyltransferase 5 accelerates tumor growth by arginine methylation of the tumor suppressor programmed cell death 4 Cancer Res. 2011, 71, 5579-87 10.1158/0008-5472.CAN-11-0458
7. Wang, L.; Pal, S.; Sif, S. Protein arginine methyltransferase 5 suppresses the transcription of the RB family of tumor suppressors in leukemia and lymphoma cells Mol. Cell. Biol. 2008, 28, 6262-77 10.1128/MCB.00923-08
8. Wei, T.-Y. W.; Juan, C.-C.; Hisa, J.-Y.; Su, L.-J.; Lee, Y.-C. G.; Chou, H.-Y.; Chen, J.-M. M.; Wu, Y.-C.; Chiu, S.-C.; Hsu, C.-P.; Liu, K.-L.; Yu, C.-T. R. Protein arginine methyltransferase 5 is a potential oncoprotein that upregulates G1 cyclins/cyclin-dependent kinases and the phosphoinositide 3-kinase/AKT signaling cascade Cancer Science 2012, 103, 1640-1650 10.1111/j.1349-7006.2012.02367.x
9. Karkhanis, V.; Hu, Y. J.; Baiocchi, R. A.; Imbalzano, A. N.; Sif, S. Versatility of PRMT5-induced methylation in growth control and development Trends Biochem. Sci. 2011, 36, 633-41 10.1016/j.tibs.2011.09.001
10. Koh, C. M.; Bezzi, M.; Low, D. H.; Ang, W. X.; Teo, S. X.; Gay, F. P.; Al-Haddawi, M.; Tan, S. Y.; Osato, M.; Sabo, A.; Amati, B.; Wee, K. B.; Guccione, E. MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis Nature 2015, 523, 96-100 10.1038/nature14351
11. Chan-Penebre, E.; Kuplast, K. G.; Majer, C. R.; Boriack-Sjodin, P. A.; Wigle, T. J.; Johnston, L. D.; Rioux, N.; Munchhof, M. J.; Jin, L.; Jacques, S. L.; West, K. A.; Lingaraj, T.; Stickland, K.; Ribich, S. A.; Raimondi, A.; Scott, M. P.; Waters, N. J.; Pollock, R. M.; Smith, J. J.; Barbash, O.; Pappalardi, M.; Ho, T. F.; Nurse, K.; Oza, K. P.; Gallagher, K. T.; Kruger, R.; Moyer, M. P.; Copeland, R. A.; Chesworth, R.; Duncan, K. W. A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models Nat. Chem. Biol. 2015, 11, 432-7 10.1038/nchembio.1810
12. Dougherty, D. A. The cation-pi interaction Acc. Chem. Res. 2013, 46, 885-93 10.1021/ar300265y
13. Antonysamy, S.; Bonday, Z.; Campbell, R. M.; Doyle, B.; Druzina, Z.; Gheyi, T.; Han, B.; Jungheim, L. N.; Qian, Y.; Rauch, C.; Russell, M.; Sauder, J. M.; Wasserman, S. R.; Weichert, K.; Willard, F. S.; Zhang, A.; Emtage, S. Crystal structure of the human PRMT5:MEP50 complex Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 17960-17965 10.1073/pnas.1209814109
14. Luo, G.; Chen, L.; Civiello, R.; Pin, S. S.; Xu, C.; Kostich, W.; Kelley, M.; Conway, C. M.; Macor, J. E.; Dubowchik, G. M. Calcitonin gene-related peptide (CGRP) receptor antagonists: Pyridine as a replacement for a core amide group Bioorg. Med. Chem. Lett. 2012, 22, 2917-2921 10.1016/j.bmcl.2012.02.065
15. Meanwell, N. A. Improving Drug Candidates by Design: A Focus on Physicochemical Properties As a Means of Improving Compound Disposition and Safety Chem. Res. Toxicol. 2011, 24, 1420-1456 10.1021/tx200211v
16. Rioux, N.; Duncan, K. W.; Lantz, R. J.; Miao, X.; Chan-Penebre, E.; Moyer, M. P.; Munchhof, M. J.; Copeland, R. A.; Chesworth, R.; Waters, N. J. Species differences in metabolism of EPZ015666, an oxetane-containing protein arginine methyltransferase-5 (PRMT5) inhibitor Xenobiotica 2015, 10.3109/00498254.2015.1072253